等待肾移植者无症状冠心病筛查的成本效用分析
本研究针对澳大利亚和新西兰成人肾移植等待者,构建马尔可夫微观模拟模型,比较等待名单后不再筛查与定期筛查无症状冠心病的经济学效果。基础分析显示不再筛查的增量成本效用比为每获得一个QALY需11122美元,并增加0.49生命年或0.35 QALY。概率敏感性分析表明在50000美元/QALY的支付阈值下,94%的模拟中不再筛查具有成本效用。
要点
- 等待名单后不再筛查无症状冠心病可能更具成本效用并改善生存。
- 移植第一年成本和冠心病患病率是影响结果的最重要变量。
- 在50000美元/QALY阈值下,94%模拟中不再筛查具有成本效用。
核心结论
- 等待名单后不再筛查无症状冠心病可能具有成本效用并可能改善生存。
研究设计与样本
- 研究采用马尔可夫微观模拟模型,基于澳大利亚和新西兰成人肾移植等待者的理论队列,从卫生系统视角进行终身 horizon 的成本效用分析。
主要发现
- 基础案例中,与定期筛查相比,不再筛查的增量成本效用比为每QALY获得11122美元。
- 不再筛查增加0.49生命年或0.35 QALY。
- 单因素敏感性分析确定移植第一年成本和冠心病患病率为最具影响力的变量。
- 概率敏感性分析显示,在每QALY获得50000美元的支付阈值下,94%的模拟中不再筛查具有成本效用。
关键数值与推荐
- 增量成本效用比:每QALY获得11122美元(基础案例,不再筛查 vs 定期筛查)。
- 生存增益:0.49生命年或0.35 QALY(不再筛查 vs 定期筛查)。
- 概率敏感性分析:94%的模拟在50000美元/QALY阈值下具有成本效用。
临床怎么用
- 对于澳大利亚和新西兰的肾移植等待者,等待名单后不再定期筛查无症状冠心病可能是一种具有成本效用的策略,并可能改善生存。
局限性
- 当代等待者和移植受者中心血管事件发生率有限。
- 结果可能不适用于澳大利亚和新西兰以外的人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: On account of the high prevalence of cardiovascular disease in patients with kidney failure, clinical practice guidelines recommend regular screening for asymptomatic coronary artery disease (CAD) in patients on the kidney transplant waitlist. To date, the cost-effectiveness of such screening has not been evaluated. A Canadian-Australasian randomized controlled trial of screening kidney transplant candidates for CAD (CARSK) is currently is being conducted to answer this question. We conducted a cost-utility analysis to determine, before completion of the trial, the cost-effectiveness of no further screening versus regular screening for asymptomatic CAD and to evaluate potential influential variables that may affect results of the economic evaluation. STUDY DESIGN: A modeled cost-utility analysis. SETTING & POPULATION: A theoretical cohort of adult Australian and New Zealand kidney transplant candidates on the waitlist. INTERVENTION: No further screening for asymptomatic CAD versus regular protocolized screening (annual or second yearly) for CAD after kidney transplant waitlisting. OUTCOMES: Incremental cost-effectiveness ratio, reported as cost per quality-adjusted life-year (QALY). MODEL, PERSPECTIVES, & TIMEFRAME: Markov microsimulation model, health system perspective and over a lifetime horizon. RESULTS: In the base case, the incremental cost-effectiveness ratio of no further screening was $11,122 per QALY gained when compared with regular screening. No further screening increased survival by 0.49 life-year or 0.35 QALY. One-way sensitivity analyses identified the costs of transplantation in the first year and CAD prevalence as the most influential variables. Probabilistic sensitivity analyses showed that 94% of the simulations were cost-effective below a willingness-to-pay threshold of $50,000 per QALY gained. LIMITATIONS: Rates of cardiovascular events in waitlisted candidates and transplant recipients are limited in the contemporary era. The results may not be generalizable to populations outside Australia and New Zealand. CONCLUSIONS: No further screening for CAD after waitlisting is likely to be cost-effective and may improve survival. Precision around CAD prevalence estimates and health care resource use will reduce existing uncertainty.
引用
- Ying T, Tran A, Webster AC, et al. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis. Am J Kidney Dis. 2019. PMID: 31810731. doi:10.1053/j.ajkd.2019.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。